Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 188

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Clinical Benefit of Statin Pretreatment in Patients Undergoing Percutaneous Coronary Intervention: A Collaborative Patient-Level Meta-Analysis of 13 Randomized Studies

Open access
Patti, Giuseppe, Cannon, Christopher P., Murphy, Sabina A., Mega, Simona, Pasceri, Vincenzo, Briguori, Carlo, Colombo, Antonio, Yun, Kyeong Ho, Jeong, Myung Ho, Kim, Jung-Sun, Choi, Donghoon, Bozbas, Huseyin, Kinoshita, Masayoshi, Fukuda, Keiichi, Jia, Xin-Wei, Hara, Hidehiko, Cay, Serkan, Di Sciascio, Germano · 2011 · Circulation

Abstract

Background—: Previous studies suggested that statin pretreatment reduces cardiac events in patients undergoing percutaneous coronary intervention. However, most data were observational, and single randomized trials included limited numbers of patients. Methods and Results—: We performed a collaborative meta-analysis using individual patient data from 13 randomized studies in which 3341 patients received either high-dose statin (n=1692) or no statin/low-dose statin (n=1649) before percutaneous coronary intervention, with all patients receiving statin therapy after intervention. Occurrence of periprocedural myocardial infarction, defined as postintervention creatine kinase–MB increase ≥3 times the upper limit of normal, and 30-day major adverse cardiac events (death, myocardial infarction, target-vessel revascularization) was evaluated. Incidence of periprocedural myocardial infarction was 7.0% in the high-dose statin versus 11.9% in the control group, which corresponds to a 44% risk reduction in the active-treatment arm (odds ratio by fixed-effects model 0.56, 95% confidence interval, 0.44 to 0.71, P <0.00001). The rate of major adverse cardiac events at 30 days was significantly lower in the high-dose statin group (7.4% versus 12.6%, a 44% risk reduction; P <0.00001), and 1-month major adverse cardiac events, excluding periprocedural events, were also reduced (0.6% versus 1.4%; P =0.05). The benefit of high-dose statins was realized irrespective of clinical presentation ( P for interaction=0.43) and was maintained across various subgroups but appeared greater in the subgroup with elevated baseline C-reactive protein levels (n=734; 68% risk reduction for periprocedural myocardial infarction versus 31% in those 1861 patients with normal CRP; P for quantitative interaction=0.025). Conclusions—: High-dose statin pretreatment leads to a significant reduction in periprocedural myocardial infarction and 30-day adverse events in patients undergoing percutaneous coronary intervention. This strategy should be considered in all patients with planned percutaneous coronary intervention.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.110.002451

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 188

Metadata

Authors
Patti, G., Cannon, C. P., Murphy, S. A., Mega, S., Pasceri, V., Briguori, C., Colombo, A., Yun, K. H., Jeong, M. H., Kim, J.-S., Choi, D., Bozbas, H., Kinoshita, M., Fukuda, K., Jia, X.-W., Hara, H., Cay, S., & Di Sciascio, G.
Venue
Circulation
Published
2011-04-19
Volume
123
Issue
15
Pages
1622-1632
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2075139068
Cited by
188
References
4
FWCI
21.09
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical Benefit of Statin Pretreatment in Patients Undergoing Percutaneous Coronary Intervention: A Collaborative Patient-Level Meta-Analysis of 13 Randomized Studies. https://app.cochat.ai/papers/10.1161/circulationaha.110.002451
The paper
Patti, G., Cannon, C. P., Murphy, S. A., Mega, S., Pasceri, V., Briguori, C., Colombo, A., Yun, K. H., Jeong, M. H., Kim, J.-S., Choi, D., Bozbas, H., Kinoshita, M., Fukuda, K., Jia, X.-W., Hara, H., Cay, S., & Di Sciascio, G. (2011). Clinical Benefit of Statin Pretreatment in Patients Undergoing Percutaneous Coronary Intervention: A Collaborative Patient-Level Meta-Analysis of 13 Randomized Studies. Circulation. https://doi.org/10.1161/circulationaha.110.002451

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.